Kato, M., Ikeda, K., Kageyama, T., Kasuya, T., Kumagai, T., Furuya, H., et al. (2019) Sucessful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum with Multidisciplinary Therapy Including Tofacitinib in a Patient with Anti-MDA5 Antibody—Positive Dermatomyositis. Journal of Clinical Rheumatology, Publish Ahead of Print.
https://doi.org/10.1097/RHU.0000000000000984

has been cited by the following article:

• TITLE: Tofacitinib as a Treatment for Refractory Dermatomyositis: A Case Report

  AUTHORS: Samuel Katsuyuki Shinjo, Fernando Henrique Carlos de Souza

  KEYWORDS: Dermatomyositis, Immunosuppressive Agents, Muscle Diseases, Myositis, Therapeutics

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.10 No.1, February 28, 2020

  ABSTRACT: In very scarce case reports and case series, tofacitinib has been a therapeutic alternative for dermatomyositis. To corroborate the literature, we described a refractory dermatomyositis that had a good outcome with tofacitinib. Case Report: An adult female patient presented with definite dermatomyositis and with refractoriness to high doses of intravenous and oral glucocorticoids, intravenous human immunoglobulin, several immunosuppressive drugs (methotrexate, azathioprine, and leflunomide) and two previous immunobiological drugs (rituximab and abatacept). However, the patient had a good outcome with tofacitinib. Conclusions: Tofacitinib appears to be a promising alternative therapy for refractory dermatomyositis.